# A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

> **NCT03056690** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 186 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** ASP0819
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03056690
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2018-02-27
- **Final completion:** 2018-02-27
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03056690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03056690, "A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03056690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*